In Vitro Activities of Gepotidacin (GSK2140944) and Other Antimicrobial Agents against Human Mycoplasmas and Ureaplasmas | Zendy

Ken B. Waites | Zendy; Donna M. Crabb | Zendy; Li Xiao | Zendy; Lynn B. Duffy | Zendy

Open Access

In Vitro Activities of Gepotidacin (GSK2140944) and Other Antimicrobial Agents against Human Mycoplasmas and Ureaplasmas

Author(s) -

Ken B. Waites,

Donna M. Crabb,

Li Xiao,

Lynn B. Duffy

Publication year - 2017

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.01064-17

Subject(s) - mycoplasma hominis , microbiology and biotechnology , ureaplasma , ureaplasma urealyticum , mycoplasma genitalium , moxifloxacin , mycoplasma , mycoplasmataceae , levofloxacin , doxycycline , biology , mollicutes , antimicrobial , tetracycline , clindamycin , antibacterial agent , bacteroides fragilis , virology , antibiotics , chlamydia trachomatis

Gepotidacin, a novel first-in-class triazaacenaphthylene topoisomerase II inhibitor, was tested against 85 type strains and clinical isolates ofMycoplasma pneumoniae ,Mycoplasma hominis ,Mycoplasma genitalium ,Ureaplasma parvum , andUreaplasma urealyticum in comparison to levofloxacin, moxifloxacin, azithromycin or clindamycin, and tetracycline. Gepotidacin MIC90 s (μg/ml) were 0.125 (M. pneumoniae ), 0.032 (M. genitalium ), 2 (M. hominis ), and 8 (Ureaplasma species). Gepotidacin activity was not affected by resistance to fluoroquinolones, tetracyclines, or macrolides in the strains tested. Gepotidacin merits further study for treating infections caused by these organisms.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research